NCT02063958View on ClinicalTrials.gov

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 27, 2017

Study Completion Date

March 20, 2018

Conditions
Cancer
Interventions
DRUG

SNX-5422

Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.

Trial Locations (5)

20007

Georgetown University Medical Center, Washington D.C.

20892

Center for Cancer Research, National Cancer Institute, Bethesda

94305

Stanford Medicine, Stanford

85259-5499

Mayo Clinic, Scottsdale

07601

hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Esanex Inc.

INDUSTRY

NCT02063958 - Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter